The Swedish CArdioPulmonary bioImage Study (SCAPIS) is a national population-based study with approx. 30 000 randomly selected participants aged 50-64 years. The participants underwent a comprehensive investigation including imaging by computed tomography of the heart, coronary arteries and thorax, ultrasound of the carotid arteries and pulmonary function tests. They also provided blood samples and filled out extensive questionnaires. The around 5000 participants in Linköping additionally underwent an echocardiographic examination and I, together with Professor Jan Engvall, co-ordinate the SCAPIS Linköping echocardiographic study.
The principal aim of SCAPIS is to find new and in our time better ways to predict the risk of cardiovascular diseases and chronic obstructive pulmonary disease. The risk factor distribution in the population is not the same today as it was some decades ago and the development of new technologies has brought new diagnostic possibilities. When we can better predict who is at high risk of a disease, the possibilities for successful preventive measures will improve.
Besides my engagement in SCAPIS, I also conduct research that aim to better understand the rare, but serious disease pulmonary arterial hypertension (PAH) and I am involved in research projects concerning cardiac involvement in the chronic rheumatic disease systemic lupus erythematosus (SLE) and the assessment of diastolic cardiac function.
The principal aim of SCAPIS is to find new and in our time better ways to predict the risk of cardiovascular diseases and chronic obstructive pulmonary disease. The risk factor distribution in the population is not the same today as it was some decades ago and the development of new technologies has brought new diagnostic possibilities. When we can better predict who is at high risk of a disease, the possibilities for successful preventive measures will improve.
Besides my engagement in SCAPIS, I also conduct research that aim to better understand the rare, but serious disease pulmonary arterial hypertension (PAH) and I am involved in research projects concerning cardiac involvement in the chronic rheumatic disease systemic lupus erythematosus (SLE) and the assessment of diastolic cardiac function.
